ES2671134T3 - Composiciones farmacéuticas derivadas de ácido xanturénico y métodos relacionados con las mismas - Google Patents

Composiciones farmacéuticas derivadas de ácido xanturénico y métodos relacionados con las mismas Download PDF

Info

Publication number
ES2671134T3
ES2671134T3 ES05857253.8T ES05857253T ES2671134T3 ES 2671134 T3 ES2671134 T3 ES 2671134T3 ES 05857253 T ES05857253 T ES 05857253T ES 2671134 T3 ES2671134 T3 ES 2671134T3
Authority
ES
Spain
Prior art keywords
formula
acid
xanthrenic
pharmaceutical compositions
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES05857253.8T
Other languages
English (en)
Inventor
Michael Schmertzler
Mark Mitchnick
Christopher D. Cain
Stewart Shankel
Neal Bricker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Naturon Inc
Original Assignee
Naturon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naturon Inc filed Critical Naturon Inc
Application granted granted Critical
Publication of ES2671134T3 publication Critical patent/ES2671134T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K19/00—Record carriers for use with machines and with at least a part designed to carry digital markings
    • G06K19/02—Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the selection of materials, e.g. to avoid wear during transport through the machine
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K19/00—Record carriers for use with machines and with at least a part designed to carry digital markings
    • G06K19/06—Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
    • G06K19/067—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components
    • G06K19/07—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips
    • G06K19/077—Constructional details, e.g. mounting of circuits in the carrier
    • G06K19/07749—Constructional details, e.g. mounting of circuits in the carrier the record carrier being capable of non-contact communication, e.g. constructional details of the antenna of a non-contact smart card
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K19/00—Record carriers for use with machines and with at least a part designed to carry digital markings
    • G06K19/06—Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
    • G06K19/067—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components
    • G06K19/07—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips
    • G06K19/077—Constructional details, e.g. mounting of circuits in the carrier
    • G06K19/07749—Constructional details, e.g. mounting of circuits in the carrier the record carrier being capable of non-contact communication, e.g. constructional details of the antenna of a non-contact smart card
    • G06K19/07758—Constructional details, e.g. mounting of circuits in the carrier the record carrier being capable of non-contact communication, e.g. constructional details of the antenna of a non-contact smart card arrangements for adhering the record carrier to further objects or living beings, functioning as an identification tag
    • G06K19/0776—Constructional details, e.g. mounting of circuits in the carrier the record carrier being capable of non-contact communication, e.g. constructional details of the antenna of a non-contact smart card arrangements for adhering the record carrier to further objects or living beings, functioning as an identification tag the adhering arrangement being a layer of adhesive, so that the record carrier can function as a sticker

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Computer Hardware Design (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)

Abstract

Una composición farmacéutica para su uso en el tratamiento de hipertensión, edema, insuficiencia renal aguda, insuficiencia cardiaca congestiva, insuficiencia renal crónica, ascitis, aumento de la presión intraocular o síndrome nefrótico, comprendiendo la composición farmacéutica una cantidad terapéuticamente eficaz de un compuesto de fórmula I:**Fórmula** A) en la que R2 es COOR; donde R se selecciona del grupo que consiste en: H, halo, sacárido, alifático, cicloalquilo, heterocicloalquilo, arilo, heteroarilo opcionalmente sustituidos, -P(O)(ORa)(ORb) y -NRaRb, donde Ra y Rb son independientemente H, alifático, cicloalquilo, heterocicloalquilo, arilo o heteroarilo opcionalmente sustituidos; R1, R3, R5, R6 y R7 son H o halógeno; X1-R4 es (>=O) o hidroxi; X2 es -O-; y R8 es H, una aldohexopiranosa, aldopentopiranosa, aldopentofuranosa o cetosa, o D-glucosa; o B) en la que el compuesto de fórmula I es ácido xanturénico 8-0-sulfato; o una sal farmacéuticamente aceptable de A) o B); y un vehículo farmacéuticamente aceptable.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
El formato de ensayo de inhibición competitiva clásico requiere la adición simultánea de analito marcado (analito conjugado) y no marcado (de la muestra). Tanto el analito marcado como el no etiquetado compiten simultáneamente por el sitio de unión en el anticuerpo de captura monoclonal en la placa. Al igual que el formato de
5 inhibición competitiva secuencial, la señal coloreada es inversamente proporcional a la concentración del analito diana no marcado en la muestra.
La detección del analito marcado puede hacerse usando un sustrato de peroxidasa tal como TMB, que puede leerse en un lector de placas de microtitulación. Por ejemplo, con una curva estándar (1 blanco y 7 patrones) y 3 controles,
10 un formato de placa de microtitulación de 96 pocillos puede analizar 21 muestras por triplicado y 37 muestras por duplicado.
Como otro aspecto de la presente descripción, se pueden usar anticuerpos, o fragmentos de anticuerpos útiles en la presente descripción para detectar cuantitativa o cualitativamente la presencia de ácido xanturénico-8-O-β-D
15 glucósido. Esto se puede lograr, por ejemplo, mediante técnicas de inmunofluorescencia que emplean un anticuerpo marcado con fluorescencia (véase a continuación) acoplado con detección microscópica de luz, citometría de flujo o fluorimétrica.
Los anticuerpos (o fragmentos de los mismos) útiles en la presente descripción pueden emplearse, adicionalmente,
20 histológicamente, como en inmunofluorescencia o microscopía de inmunoelectrones, para la detección in situ de ácido xanturénico-8-O-β-D-glucósido. La detección in situ puede realizarse eliminando un espécimen histológico de un paciente, y aplicando al mismo un anticuerpo marcado de la presente descripción. El anticuerpo (o fragmento) se aplica opcionalmente al recubrir el anticuerpo (o fragmento) marcado en una muestra biológica. A través del uso de tal procedimiento, es posible determinar no solo la presencia del ácido xanturénico-8-O-β-D-glucósido, sino también
25 su distribución en el tejido examinado. Usando la presente descripción, los expertos en la materia percibirán fácilmente que cualquiera de una amplia diversidad de métodos histológicos (tales como procedimientos de tinción) puede modificarse para lograr tal detección in situ.
Los expertos en la técnica podrán determinar las condiciones de ensayo ópticas y operativas para cada 30 determinación empleando experimentación rutinaria.
Una de las formas en que el anticuerpo específico del péptido del gen puede marcarse de forma detectable es unirlo a una enzima y usarlo en un inmunoensayo enzimático (EIA) (Voller, Ric Clin Lab, 8: 289-98 (1978) ["The Enzyme Linked Immunosorbent Assay (ELISA)", Diagnostic Horizons 2: 1-7, 1978, Microbiological Associates Quarterly 35 Publication, Walkersville, Md.]; Voller et al., J. Clin. Pathol., 31: 507-20 (1978); Butler, Meth. Enzymol., 73: 482-523 (1981); Maggio (ed.), Enzyme Immunoassay, CRC Press, Boca Raton, Fla. (1980); Ishikawa et al., (eds.) Enzyme Immunoassay, Igaku-Shoin, Tokio (1981)). La enzima que está unida al anticuerpo reaccionará con un sustrato apropiado, opcionalmente un sustrato cromogénico, de tal manera que se produzca un resto químico que pueda detectarse, por ejemplo, por espectrofotometría, medios fluorimétricos o por medios visuales. Las enzimas que se 40 pueden usar para marcar de forma detectable el anticuerpo incluyen, pero sin limitación, malato deshidrogenasa, nucleasa estafilocócica, delta-5-esteroide isomerasa, alcohol deshidrogenasa de levadura, alfa-glicerofosfato, deshidrogenasa, triosa fosfato isomerasa, peroxidasa de rábano picante, fosfatasa alcalina, asparaginasa, glucosa oxidasa, beta-galactosidasa, ribonucleasa, ureasa, catalasa, glucosa-6-fosfato deshidrogenasa, glucoamilasa y acetilcolinesterasa. La detección se puede lograr mediante métodos colorimétricos que emplean un sustrato
45 cromogénico para la enzima. La detección también se puede realizar por comparación visual de la extensión de la reacción enzimática de un sustrato en comparación con estándares preparados de forma similar.
La detección también puede realizarse usando cualquiera de una diversidad de otros inmunoensayos. Por ejemplo, marcando radiactivamente los anticuerpos o fragmentos de anticuerpos, es posible detectar el ácido xanturénico-8
50 O-β-D-glucósido a través del uso de un radioinmunoensayo (RIA) (véase, por ejemplo, Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986). El isótopo radioactivo se puede detectar por medios tales como el uso de un contador gamma o un contador de centelleo o por autorradiografía.
55 También es posible marcar el anticuerpo con un compuesto fluorescente. Cuando el anticuerpo marcado por fluorescencia se expone a la luz de la longitud de onda adecuada, su presencia puede detectarse entonces debido a la fluorescencia. Entre los compuestos de marcado fluorescente más comúnmente utilizados están isotiocianato de fluoresceína, rodamina, ficoeritrina, ficocianina, aloficocianina, o-ftaldehído y fluorescamina.
15
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19

Claims (1)

  1. imagen1
ES05857253.8T 2004-12-29 2005-12-29 Composiciones farmacéuticas derivadas de ácido xanturénico y métodos relacionados con las mismas Active ES2671134T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/027,131 US8697674B2 (en) 2004-12-29 2004-12-29 Xanthurenic acid derivative pharmaceutical compositions and methods related thereto
US17131 2004-12-29
PCT/US2005/047474 WO2006072000A2 (en) 2004-12-29 2005-12-29 Xanthurenic acid derivative pharmaceutical compositoins and methods related thereto

Publications (1)

Publication Number Publication Date
ES2671134T3 true ES2671134T3 (es) 2018-06-05

Family

ID=36612543

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05857253.8T Active ES2671134T3 (es) 2004-12-29 2005-12-29 Composiciones farmacéuticas derivadas de ácido xanturénico y métodos relacionados con las mismas

Country Status (10)

Country Link
US (6) US8697674B2 (es)
EP (2) EP3379506A1 (es)
JP (1) JP5456975B2 (es)
KR (1) KR20080010383A (es)
CN (2) CN104069123B (es)
AU (1) AU2005321915A1 (es)
BR (1) BRPI0519764A2 (es)
CA (1) CA2593096A1 (es)
ES (1) ES2671134T3 (es)
WO (1) WO2006072000A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697674B2 (en) 2004-12-29 2014-04-15 Naturon, Inc. Xanthurenic acid derivative pharmaceutical compositions and methods related thereto
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
CN103134885A (zh) * 2011-12-01 2013-06-05 石药集团中奇制药技术（石家庄）有限公司 一种氨氯地平、缬沙坦和氢氯噻嗪复方制剂溶出度的检测方法
CN102557995A (zh) * 2011-12-14 2012-07-11 天津药物研究院药业有限责任公司 N-乙氧甲酰基-5-氯-2-甲基-4-氨磺酰基苯胺的合成方法
MA44037B1 (fr) 2016-06-06 2020-03-31 Arena Pharm Inc Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
EP3640633A1 (en) * 2018-10-16 2020-04-22 UriSalt GmbH Means for the quantitative determination of cationic electrolyte concentration and creatinine concentration and of their ratios
CN109799305A (zh) * 2019-03-28 2019-05-24 苏州旭辉检测有限公司 一种尿液样本中多种普利类降压药的检测方法
CN111647640A (zh) * 2020-05-22 2020-09-11 中国药科大学 一种快速精准实现慢性心力衰竭心功能病程分级的方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1334705A (en) 1970-06-19 1973-10-24 Ici Ltd Pharmaceutical compositions containing kynurenic acid derivatives
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
ZA801575B (en) * 1979-03-27 1981-03-25 Boots Co Ltd Therapeutic agents
JPS55151511A (en) 1979-05-16 1980-11-26 Sankyo Co Ltd Antiallergic agent consisting mainly of kynurenic ester derivative
DE2939304A1 (de) * 1979-09-28 1981-04-16 Wella Ag Mittel und verfahren zur oxidativen faerbung von haaren
GB2092130B (en) 1980-07-28 1984-05-10 Hodogaya Chemical Co Ltd 4-oximino-1,2,3,4-tetrahydroquinoline derivatives
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) * 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) * 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
DE3578374D1 (de) * 1984-01-13 1990-08-02 Boots Co Ltd Verwendung von chinolonen fuer die herstellung eines arzneimittels zur behandlung von herzerkrankungen.
US4656188A (en) * 1985-10-09 1987-04-07 Merck & Co., Inc. Ace inhibitors in macular degeneration
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5106630A (en) * 1988-07-11 1992-04-21 Neal S. Bricker Natriuretic hormone
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5124152A (en) * 1991-01-07 1992-06-23 Fisons Corporation Parenteral formulation of metolazone
US5738875A (en) * 1994-10-28 1998-04-14 R.P. Scherer Corporation Process for preparing solid pharmaceutical dosage forms
AU7602100A (en) 2000-08-18 2002-03-04 Gen Hospital Corp Method for the identification of agents that inhibit or promote cataracts and uses thereof
FR2827045B1 (fr) 2001-07-05 2007-08-10 Univ Pasteur Methodes et compositions pour la selection et le developpement de nouveaux agents pharmacologiques ou de nouveaux medicaments
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
US8697674B2 (en) * 2004-12-29 2014-04-15 Naturon, Inc. Xanthurenic acid derivative pharmaceutical compositions and methods related thereto
CA2608476A1 (en) 2005-06-28 2007-01-04 Bausch & Lomb Incorporated Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of gelatinase a in ocular cells

Also Published As

Publication number Publication date
AU2005321915A1 (en) 2006-07-06
US8697674B2 (en) 2014-04-15
WO2006072000A2 (en) 2006-07-06
EP1851739B8 (en) 2018-05-23
KR20080010383A (ko) 2008-01-30
US20100092999A1 (en) 2010-04-15
WO2006072000A3 (en) 2008-12-24
US20130157295A1 (en) 2013-06-20
EP3379506A1 (en) 2018-09-26
US8034576B2 (en) 2011-10-11
CN101443823A (zh) 2009-05-27
EP1851739A4 (en) 2012-08-29
US20060142248A1 (en) 2006-06-29
JP2008537928A (ja) 2008-10-02
CA2593096A1 (en) 2006-07-06
US10370335B2 (en) 2019-08-06
JP5456975B2 (ja) 2014-04-02
US8361734B2 (en) 2013-01-29
US20140309180A1 (en) 2014-10-16
EP1851739A2 (en) 2007-11-07
CN104069123A (zh) 2014-10-01
US20060217322A1 (en) 2006-09-28
CN101443823B (zh) 2014-06-04
BRPI0519764A2 (pt) 2009-03-10
EP1851739B1 (en) 2018-02-28
CN104069123B (zh) 2016-10-05
US20120028280A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
ES2671134T3 (es) Composiciones farmacéuticas derivadas de ácido xanturénico y métodos relacionados con las mismas
US20220155316A1 (en) Protein sequencing methods and reagents
González-Buitrago et al. Urinary proteomics
CN1700009A (zh) 用单一捕获剂定量检测特异性分析物的方法及其试剂盒
RU2001102598A (ru) Способ ранней диагностики карцином
Thongboonkerd Study of diabetic nephropathy in the proteomic era
Lim et al. Phosphoproteomic fingerprinting of epidermal growth factor signaling and anticancer drug action in human tumor cells
Zuo et al. Determination of β-adrenergic agonists by hapten microarray
WO2011008682A1 (en) Urinary trypsin inhibitors as diagnostic aid for interstitial cystitis
US20080193931A1 (en) Method of rapidly quantifying global DNA methylation
EP3264085A1 (en) Immunoassay method and assay reagent used in said method
RU2011140006A (ru) Способ детекции вещества в биологическом образце
CN113588942B (zh) 一种检测抗原肌球蛋白1-IgG抗体的试剂盒
Straw et al. Proof of concept study to identify candidate biomarkers of fibrosis using high throughput peptide aptamer microarray and validate by enzyme linked immunosorbant assay
CN113884670A (zh) 一种免疫学检测的信号放大材料及其制备方法
US10883989B2 (en) Peptides of M. tuberculosis for a screening test for HIV positive patients at high-risk for tuberculosis
US9921225B2 (en) Phenyl glyoxal probes
DE102005051978A1 (de) Verfahren zur Bestimmung der Spaltbarkeit von Substraten
EP0807254A1 (en) Luminescent probes for protein detection
WO2021048345A1 (en) Lateral flow immunoassay device for detection of candida infection and uses thereof
JP4795353B2 (ja) 腫瘍疾患および慢性炎症性腸疾患の診断のための液性バイオマーカーとしてのカルバモイルリン酸合成酵素１（ｃｐｓ１）の使用
CN117025548B (zh) 鼠抗SARS-CoV-2 Spike蛋白杂交瘤细胞株、抗体、试剂盒及应用
JP2005017264A (ja) 発現微量タンパク質／ペプチドの検出・分離・同定法
EP1057034A1 (en) Assay for detection of phosphate or carbohydrate groups on serine residues
US20230236170A1 (en) Reactive affinity probe-interaction discovery platform